Man, this thing sure looks like a low floater. The TA told you guys the OS was 49 million, but the last time the company listed it was 14 million. I wonder how much of that 49 million is free-trading.

From Mark Smith. He gave me the number of the lawyer who handled the deal but I didn't get a hold of him yet.

Is anybody home? We have a developing story on the TMXU shell. Mark Smith has moved this shell. I'm trying to get the details...

He confirmed what Abe Grossman's lawyer said about PLSO and he told me what I posted on some of the boards today about TMXU. He has sold it.

I hope he has saved a good one for us!

TMXU heads up:

I spoke with Mark Smith yesterday. He has sold this shell. It nearly doubled on Friday on light volume and was a 50 bagger back in May on only 4 million shares, so it appears to be a low floater that can explode on news. He gave me the number of the lawyer who worked the deal, but I was unable to get a hold of him. I'll try again today.

An announcement will run this a long way.

TMXU heads up:

I spoke with Mark Smith yesterday. He has sold this shell. It nearly doubled on Friday on light volume and was a 50 bagger back in May on only 4 million shares, so it appears to be a low floater that can explode on news. He gave me the number of the lawyer who worked the deal, but I was unable to get a hold of him. I'll try again today.

An announcement will make this fly.

TMXU heads up:

I spoke with Mark Smith yesterday. He has sold this shell. It nearly doubled on Friday on light volume and was a 50 bagger back in May on only 4 million shares, so it appears to be a low floater that can explode on news. He gave me the number of the lawyer who worked the deal, but I was unable to get a hold of him. I'll try again today.

An announcement should be quite explosive.

This has to be a special shell for Mark Smith right? After all this is Mark's toys and entertainment.

I talked with Mark Smith today. He said he's in the process of getting this shell ready to go. He didn't know what the share count was because he has a lot of shells. It didn't seem to be a significant factor for him. He said he sells these through his lawyers, and he's worked with a few different ones. I was surprised that I got a hold of him and that he was willing to answer all of my questions.

I should have requested that he match us up with a twin company to RGNO, but I just thought of that now as I'm writing this.

Okay, so somebody call him tomorrow and make that request. He was very accommodating, maybe he'll look out for a special one to match up with his toy.

According to pink sheets the OS is only 12 million here.

MRXT -- Marx Toys & Entertainment Corp.

Officers:
Mark Smith, President/CFO/Secretary

Fiscal Year End: December 31

Edgar Filing Status: Non EDGAR Filer

Outstanding Shares: 12,671,240 as of 2002-11-26

Estimated Market Cap: Not Available
Authorized Shares: 200,000,000 as of 2006-01-26

I'll tell you that it looks overvalued at this point. All of the shells on the list that I just checked except LNBO dipped below .001 at some point. LNBO dipped to a low of .005. It's still being traded above that.

Some of these shells lie dormant for years. This looks like an attractive one for whoever scoops it up, but why does it take so long for some of these to get reinstated? Particularly ones with low OS. Is there a bankruptcy time restriction or do some of these just go unnoticed?

I'm still new to the shell game, so I don't know how this works. I know of a company that went bankrupt last year and had less than 15 mil OS. Is that shell available at any time, or is there a waiting period before someone can acquire it, and what is the going rate for a shell?

we've seen the connections they built with some major players - roche and amgen are huge of course - and they've built impressive reputations. They've spoken at many conferences and have sat on many committees.

It's starting to look like they have also been quietly building a portfolio of promising drug candidates and other products for a few years now in anticipation of making this move. Their backgrounds all point to this being a group of careful, meticulous guys (Martel included).

I think they waited until they could assemble an impressive pipeline before going public.

Dov Pharmaceuticals went to over $20.00 per share last year on 22 million shares outstanding. In biotech, you can avoid dilutive financing by forming partnerships with big pharma if your drug candidates or other potential products are lucrative and show early promising results.

I like filet mignon, medium rare.

The big rise that moved this to 3 cents occured before anyone had talked to the owners.

So let me get this straight. You're saying that a company comes in and gets 65 million shares for it's teenie weenie 10 million dollar company, the public runs it's share price over a dollar a share, and that company will feel like it's been raped for making $65 million off of it's 10 million dollars in revenue.

Now, who's on sesame street here, pink snuffalufogus? Q: Why do you suppose that reverse mergers are on the rise? Allow me to do the math for you. A: To gain access to public money.

CSBR is on the move...

Champions Biotechnology, Inc. Acquires Rights to Cancer Drug Candidates
ARLINGTON, Va., Feb. 14 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC: CSBR) (BULLETIN BOARD: CSBR) , a development stage biotechnology company, announced today the acquisition of patent rights encompassing two Benzoylphenylurea (BPU) sulfur analog compounds that have shown promising potent activity against prostate and pancreatic cancer cell lines (Journal of Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360). The acquired rights include pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.

These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau) deficient tumors, a common feature of solid tumors, and have performed better than Docetaxel (Taxotere) in the difficult to treat direct patient xenograft models of pancreatic cancer (Journal of the National Cancer Institute, Vol. 99, Issue 2, January 17 2007, 105-107). The Company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University by their inventors Drs. Saeed Khan, Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno.

This acquisition is the Company's initial step in building a biotechnology company from the ground up with a future portfolio of possible therapeutic drug candidates among other ventures that it is actively exploring. The Company plans to develop candidates from its portfolio of therapeutic compounds and partner with pharmaceutical and/or biotechnology partners for development, regulatory approval and marketing as appropriate.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. The Company generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors, which may include, but are not limited to, changes in general economic conditions, the ongoing threat of terrorism, ability to have access to financing sources on reasonable terms and other risks that are described in this document. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and the Company's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

The gap actually goes as far back as .01.

That's right folks, we have to go all the way down to one cent per share before the share price can move upward any further. The gap is clearly there.

Fortunatly, I was hoping to purchase 100,000 more shares before we went into the dollars per share range for good. The chart clearly shows that I'll be able to do that before the gap is filled.

It doesn't matter if we announce the biggest partnership in biotech history tomorrow. Defying that gap would be nothing short of defying one of the laws of thermodynamics.

Buy all you want tomorrow, but when my order for 100,000 shares gets filled at .01, I'll be on a buying spree at the



gap.

This acquisition is the Company's initial step in building a biotechnology company from the ground up with a future portfolio of possible therapeutic drug candidates among other ventures that it is actively exploring. The Company plans to develop candidates from its portfolio of therapeutic compounds and partner with pharmaceutical and/or biotechnology partners for development, regulatory approval and marketing as appropriate.

Only 550,000 restricted shares to acquire worldwide rights to the candidates that showed more potency than taxotere. Not a bad deal. It looks like we're building a nice connection to the best that Johns Hopkins has to offer.

It's funny, everytime I brought up the diagnostic angle yesterday Martel would say something like, "There are a lot of promising areas to explore in the field, drugs, diagnostics..."

Here we go boys and girls. Looks like we're just getting warmed up here. Here come the dollars!

morning John. We're gonna run a little today.

I just had a very positive phone call with Jim Martel. I called to make my case for developing Champions Biotech into a diagnostic company. I told him that I thought an announcement of such a move would send the share price to a couple of dollars a share. Then they could move towards working with investment banking firms. He said there are many promising areas, drugs, diagnostics.

He said "we're moving forward, not standing still. We're confident that we're heading in the right direction." From a guy that doesn't like to hype or divulge any information prematurely, that was all I needed to hear.

He said that it took a couple of days to return my phone call because he has been very busy.

Something's in the works ladies and gentlemen. They have something they're ready to go with already.

He said that he and Durwood Settles are the two directors. They had a CFO but he died last year. He said they are as lean as a company can get. And, to me he sounded slightly giddy.

Nice move today. Come on, run it to a dollar! We're due for more news soon. A dollar will be cheap after that.

From what I heard recently, Abe has been working out the necessary steps to complete a reverse merger. We should see the results of that work soon.

A beer sounds good to me too.

That's the one that we've talked about on the board already. After the reverse merger the share price went to $6.50 a share.

Because Mark Smith has a few shells in his name out there, each one that he unloads brings us closer to our turn to be the vehicle for a reverse merger.

It wasn't Mark Smith's decision to reverse split. But now he has one less shell in his collection. With the tiny OS, TINV will probably fly once the reverse merger is announced anyway.

I like that TINV was sold and shipped out to Frank Pioppi, who reverse split it to a few hundred thousand shares. We're one closer to MRXT's turn.

So it looks like there are about 115 million shares outstanding here. So we have a market cap of about $230,000, with Mark Smith in control, and a clean shell. Not bad.

It seems like this one has been overlooked. Any reasons we haven't seen our run to three cents yet? Just bad luck, or is there something amiss here?

I like that this is a reporting company, it makes it more attractive to me. What about the six million worth of debt? Wouldn't a merging company have to assume that?

Do you think they can produce a net profit with their projected $4 million in revenues for 2007?

It wouldn't take much to turn this around. Still little resistance between here and multi-dollars.

Wow this is a lefty fest. I love it!

Would you settle for extreme panic selling, followed at the by a PR at the end of the day stating that they have just developed an extremely accurate test to detect lung cancer at a very curable stage?

Hurrah fellow lefty. Congrats on adding a few here too. I'd love to get that opportunity too. Let's see a panic sell so I can reach my goal.

We're getting near lift-off here. We know from conversations with Abe Grossman last week that the reverse merger is coming soon.

When this runs to two cents again, you can say goodbye to subpenny for good.

Yeah, the gamble going on currently seems to be, try to get more lower before the next announcement comes. Because it has been over two weeks since the announcement people are starting to get the itchy trigger finger.

Years of playing penny stocks will tend to do that to you.

I believe that the doctors will incorporate their years of stellar research into this play. Even if that is not the case, we're still going to get a biotech looking to go public in a clean shell with a low OS and a CEO with a long history of being frugal with his public company.

PPXP is a recent example of a biotech that went public in a low float vehicle. It went from .50 to it's current price of around $6.50 a share. If nothing else, I have to believe that the doctors will try to maximize their investments and their friend's by finding the most promising group out there to merge into CSBR.

Why do you say that?

We all knew that this would be a volatile play until the RM gets announced. Anyone sitting on the outside will avoid the volatility, but miss out on a substantial part of the run when the merger news comes.

What's the share count on RGNO?

I highly doubt that this venture is an attempt by the doctors to make a quick buck. I think they're trying to build something here, not just to announce something big and sell on the news.

I'm liking my future. Bring on the merger!

Great day, fringe. Thanks for your great DD. It looks like we have some exciting news coming our way soon. :)

I'll try. We have to bring volume in here. There have been so many plays like ATLJ, where people see the green light and the volume explodes.

I think we have a green light situation here with the RM on the horizon. With the low float, the reward will be much greater here than ATLJ or FCCN, where the share count turned out to be much higher.